Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC). Tannir, N. M., Fan, A. C., Lee, R. J., Carthon, B., Iliopoulos, O., Mier, J., Patel, M. R., Meric-Bernstam, F., DeMichele, A., Voss, M., Harding, J. J., Srinivasan, R., Shapiro, G., Telli, M. L., Munster, P. N., Carvajal, R. D., Jenkins, Y., Whiting, S. H., Bendell, J. C., Bauer, T. AMER SOC CLINICAL ONCOLOGY. 2018
View details for DOI 10.1200/JCO.2018.36.6_suppl.603
View details for Web of Science ID 000436179500597